Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

SAN DIEGO, Aug. 25 /PRNewswire/ -- NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

DAS181 (Fludase((R))) is an investigational drug candidate in clinical development for Influenza-Like Illness. Unlike neuraminidase inhibitors (e.g. Tamiflu((R))), which target the virus, DAS181 works by inactivating the human host receptor for all influenza and para-influenza viruses tested so far including the current pandemic Novel H1N1 strain ("Swine Flu"). Previous preclinical studies conducted in collaboration with the Centers for Disease Control and Prevention have shown DAS181 to have significant prophylactic and therapeutic activity in an in vivo animal model for a highly virulent H5N1 (A/VN/1203/04) strain of influenza. The current published study, conducted in collaboration with the University of Hong Kong, examined for the first time the effects of DAS181 in human lung tissue and cells. DAS181 strongly inhibited H5N1 (A/VN/3046/2004) infection in human lung tissue and cells. The study also demonstrated that DAS181 effectively removes the two types of sialic acid (Sia) receptors to which influenza virus binds, thereby preventing both the invasion by virus into new cells and further replication where infection already exists.

The human lung tissue and cells described have been critical models for understanding the clinical pathogenesis of influenza, as people contain two types of receptors for influenza. While H5N1 preferentially binds to A2-3-linked Sia, Novel H1N1 preferentially binds to A2-6-linked Sia. DAS181 was shown in these studies to remove both the A2-6-linked and A2-3-linked types found in human respiratory tissue. Most importantly, virus was suppressed by inactivation of the entry receptors by DAS181 treatment.
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Neogen Corporation (Nasdaq: NEOG ... quarter of its 2015 fiscal year, which ended Aug. ... net income of $7,839,000 in the first quarter of ... Oct. 30, 2013, earnings per share in the current ... First quarter revenues increased 15% to $67,599,000, ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
(Date:9/21/2014)... September 21, 2014 Chemical Sciences ... challenges such as clean air and safe water, ... natural products. Chemists, environmentalists, food scientists, educators, and ... research in the field of Chemistry for the ... Sciences is one of the fastest emerging Sciences, ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Inc. (PDL, the Company) (NASDAQ: PDLI ) today ... other conditions, $135 million aggregate principal amount of new convertible ... statement filed with the U.S. Securities and Exchange Commission (SEC) ... the underwriters a 13-day overallotment option to purchase up to ...
... SPRING, Md., May 9, 2011 The U.S. Food and ... public relating to the development of a user fee ...   (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... as a microorganism, plant, or animal cell, while small ...
... 2011 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the U.S. Securities and Exchange ... Statement relating to the previously announced acquisition of TomoTherapy ... registration statement will first be mailed to TomoTherapy shareholders ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:9/22/2014)... fishes that manufacture their own "antifreeze" proteins to ... an unfortunate side effect, researchers report: The protein-bound ... melting even when temperatures warm. , The ... the National Academy of Sciences . , "We ... of the evolution of antifreeze proteins in Antarctic ...
(Date:9/22/2014)... 2014)The Brain & Behavior Research Foundation ... Young Investigator Grants valued at more than ... most promising young scientists. Recipients of the ... will seek to identify causes, improve treatments ... that affect one in four people, including ...
(Date:9/22/2014)... more useful in homes, if they could locate people, ... with cameras and lasers, which have difficulty reliably recognizing ... clutter. A complementary way robots can "sense" what is ... frequency radio-frequency identification (UHF RFID) tags. Inexpensive self-adhesive tags ... to search a room for the correct tag,s signal, ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... Karen Burg and her colleagues in the Institute for ... means of studying the complex behavior of cancer cells ... way doctors treat the disease. With support from ... the researchers are building scaffolds that mimic the three-dimensional ...
... diseases is a hot area of scientific research, primarily ... the context of atherosclerotic disease. Scientists have engineered a ... about the conditions under which nanoparticles accumulate in the ... of myocardial infarction and stroke. In the research, ...
... blood platelets and bone marrow cells to deliver potentially ... genetic disorder Hurler syndrome an often fatal condition ... Scientists from Cincinnati Children,s Hospital Medical Center and the ... their unique strategy for treating the disease the week ...
Cached Biology News:In vitro innovation: Testing nanomedicine with blood cells on a microchip 2In vitro innovation: Testing nanomedicine with blood cells on a microchip 3Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
DNA fragmentation factor & Inhibitor of CAD...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: